Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed + Doxorubicin vs AC in Neoadjuvant Breast Cancer
NCT00149214Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2005
- Primary completion
- Feb 2008
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of pemetrexed in breast cancer (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Pathological Complete Response. Started Sep 2005; status: completed.
02
Drugs
pemetrexed
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00149214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00149214.